Evidence map›Paper›PMID 29444080›Full record

ArticlePLoS neglected tropical diseases2018

Promising approach to reducing Malaria transmission by ivermectin: Sporontocidal effect against Plasmodium vivax in the South American vectors Anopheles aquasalis and Anopheles darlingi.

Yudi T Pinilla, Stefanie C P Lopes, Vanderson S Sampaio, Francys S Andrade, Gisely C Melo, Alessandra S Orfanó, Nágila F C Secundino, Maria G V B Guerra, Marcus V G Lacerda, Kevin C Kobylinski and 8 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Ivermectin treatment in humans for reducing malaria transmission.The Cochrane database of systematic reviews · 2021
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Identification of the metabolites of ivermectin in humans.Pharmacology research & perspectives · 2021
    Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Efficacy of ivermectin and its metabolites againstAntimicrobial agents and chemotherapy · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 4 countries.

Yudi T PinillaInternational Center for Clinical Research in Malaria, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.
Stefanie C P LopesInternational Center for Clinical Research in Malaria, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.
Vanderson S SampaioInternational Center for Clinical Research in Malaria, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.
Francys S AndradeInternational Center for Clinical Research in Malaria, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.
Gisely C MeloInternational Center for Clinical Research in Malaria, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.
Alessandra S OrfanóCentro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Nágila F C SecundinoCentro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Maria G V B GuerraInternational Center for Clinical Research in Malaria, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.
Marcus V G LacerdaInternational Center for Clinical Research in Malaria, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.
Kevin C KobylinskiDepartment of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Karin S Escobedo-VargasDepartment of Entomology, U.S. Naval Medical Research Unit No. 6 (NAMRU-6), Callao, Peru.
Victor M López-SifuentesDepartment of Entomology, U.S. Naval Medical Research Unit No. 6 (NAMRU-6), Callao, Peru.
Craig A StoopsDepartment of Entomology, U.S. Naval Medical Research Unit No. 6 (NAMRU-6), Callao, Peru.
G Christian BaldevianoDepartment of Entomology, U.S. Naval Medical Research Unit No. 6 (NAMRU-6), Callao, Peru.
Joel TarningMahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Gissella M VasquezDepartment of Entomology, U.S. Naval Medical Research Unit No. 6 (NAMRU-6), Callao, Peru.
Paulo F P PimentaInternational Center for Clinical Research in Malaria, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.
Wuelton M MonteiroInternational Center for Clinical Research in Malaria, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.ORCID 0000-0002-0848-1940
Fundação de Medicina Tropical · BRUnited States Naval Medical Research Unit SOUTH · PEFundação Oswaldo Cruz · BRArmed Forces Research Institute of Medical Science · THMahidol University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe mosquito resistance to the insecticides threatens malaria control efforts, potentially becoming a major public health issue. Alternative methods like ivermectin (IVM) administration to humans has been suggested as a possible vector control to reduce Plasmodium transmission. Anopheles aquasalis and Anopheles darlingi are competent vectors for Plasmodium vivax, and they have been responsible for various malaria outbreaks in the coast of Brazil and the Amazon Region of South America.

methodsTo determine the IVM susceptibility against P. vivax in An. aquasalis and An. darlingi, ivermectin were mixed in P. vivax infected blood: (1) Powdered IVM at four concentrations (0, 5, 10, 20 or 40 ng/mL). (2) Plasma (0 hours, 4 hours, 1 day, 5, 10 and 14 days) was collected from healthy volunteers after to administer a single oral dose of IVM (200 μg/kg) (3) Mosquitoes infected with P. vivax and after 4 days was provided with IVM plasma collected 4 hours post-treatment (4) P. vivax-infected patients were treated with various combinations of IVM, chloroquine, and primaquine and plasma or whole blood was collected at 4 hours. Seven days after the infective blood meal, mosquitoes were dissected to evaluate oocyst presence. Additionally, the ex vivo effects of IVM against asexual blood-stage P. vivax was evaluated.

resultsIVM significantly reduced the prevalence of An. aquasalis that developed oocysts in 10 to 40 ng/mL pIVM concentrations and plasma 4 hours, 1 day and 5 days. In An. darlingi to 4 hours and 1 day. The An. aquasalis mortality was expressively increased in pIVM (40ng/mL) and plasma 4 hours, 1, 5 10 and 14 days post-intake drug and in An. darlingi only to 4 hours and 1 day. The double fed meal with mIVM by the mosquitoes has a considerable impact on the proportion of infected mosquitoes for 7 days post-feeding. The oocyst infection prevalence and intensity were notably reduced when mosquitoes ingested blood from P. vivax patients that ingested IVM+CQ, PQ+CQ and IVM+PQ+CQ. P. vivax asexual development was considerably inhibited by mIVM at four-fold dilutions.

conclusionIn conclusion, whole blood spiked with IVM reduced the infection rate of P. vivax in An. aquasalis and An. darlingi, and increased the mortality of mosquitoes. Plasma from healthy volunteers after IVM administration affect asexual P. vivax development. These findings support that ivermectin may be used to decrease P. vivax transmission.

Indexed as

AnimalsAnophelesBrazilChloroquineDose-Response Relationship, DrugDrug CombinationsFemaleHumansInsect VectorsIvermectinMalariaOocystsPlasmodium vivaxPrimaquineChloroquineDrug CombinationsIvermectinPrimaquine

Identifiers

PMID29444080
PMCPMC5828505
OpenAlexW2787257466

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.